Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) CEO John L. Knopf sold 17,500 shares of Acceleron Pharma stock on the open market in a transaction dated Monday, July 7th. The stock was sold at an average price of $31.74, for a total value of $555,450.00. Following the sale, the chief executive officer now directly owns 174,000 shares of the company’s stock, valued at approximately $5,522,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded up 4.03% during mid-day trading on Wednesday, hitting $30.21. 166,640 shares of the company’s stock traded hands. Acceleron Pharma has a 52-week low of $16.78 and a 52-week high of $57.89. The stock’s 50-day moving average is $32.33 and its 200-day moving average is $38.69. The company’s market cap is $950.3 million.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Thursday, May 15th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.14. The company had revenue of $3.31 million for the quarter, compared to the consensus estimate of $2.85 million. On average, analysts predict that Acceleron Pharma will post $-1.24 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.